We came across a bullish thesis on Hims & Hers Health, Inc. on PatchTogether Investing’s Substack. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.'s share was trading at $48.11 as of September 4th. HIMS’s trailing and forward P/E were 60.90 and 62.50 respectively according to Yahoo Finance. Hims & Hers (NYSE: HIMS) saw its stock fall 30% after Q2 2025 earnings as investors questioned whether its growth story is losing steam. Revenue fell sequentially for the first t ...

The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy. ...

SPECIAL REPORT: Here's The Most Trusted Company For Investing Hims stock toppled Tuesday after the Food and Drug Administration issued the telehealth giant a warning letter regarding its knockoff version of Novo Nordisk's semaglutide. The Pressure On Hims Stock Hims & Hers Health is a telehealth giant with a compounding business. The company sells skin care, sexual health and hair-loss products. But Hims became a household name when the company launched its compounded semaglutide in May 2024. At the time, b ...

Key Takeaways HIMS appoints Mo Elshenawy as CTO to accelerate its AI-powered digital health platform strategy.Hims & Hers' recent $870 million convertible notes raise will fund AI, diagnostics and global tech expansion.HIMS leverages proprietary algorithms and cloud systems to scale personalized virtual care delivery.The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , is actively deepening its technology integration to transform how healthcare is delivered. The company recently appo ...

FDA强调，复合型药物产品本身并未获得FDA批准，因此不得将其等同于经过临床试验和审批的标准药 品。监管机构已要求Hims&Hers在15个工作日内提交整改措施，若未能有效应对相关问题，可能将面临 包括扣押产品、发布禁令在内的法律制裁。 周二，Hims&Hers Health(HIMS.US)股价走低，截至发稿，该股跌超7%，报49.99美元。此前该公司因 其关于"复合型司美格鲁肽"产品的宣传内容收到美国食品药品监督管理局(FDA)的正式警告信。 ...

FDA强调，复合型药物产品本身并未获得FDA批准，因此不得将其等同于经过临床试验和审批的标准药 品。监管机构已要求Hims & Hers在15个工作日内提交整改措施，若未能有效应对相关问题，可能将面 临包括扣押产品、发布禁令在内的法律制裁。 智通财经APP获悉，周二，Hims & Hers Health(HIMS.US)股价走低，截至发稿，该股跌超7%，报49.99 美元。此前该公司因其关于"复合型司美格鲁肽"产品的宣传内容收到美国食品药品监督管理局(FDA)的 正式警告信。 ...

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $54.03, marking a -2.65% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow experienced a rise of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.94%. The stock of company has risen by 20.6% in the past month, leading the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32%.Market participants will be closely following the financial results of Him ...

PHILADELPHIA , Sept. 15, 2025 /PRNewswire/ --Â Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers. ...

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with stron ...

FDA此次表态前，美国总统唐纳德·特朗普已于本周二签署一份总统备忘录，敦促其政府加强对面向消 费者(DTC)的药品广告法规的执法力度，以确保广告内容的透明度与准确性。 同日，FDA宣布将向制药公司发出约100份终止令和数千封警告信，提醒企业遵守面向消费者的药品广 告规则。 智通财经APP获悉，美国食品药品监督管理局(FDA)局长马丁·马卡里于上周五表示，Hims & Hers公司 (HIMS.US)在超级碗期间投放的广告违反了联邦法律。该广告仅强调了减肥药物的益处，却未提及任何 副作用。 马卡里在《美国医学会杂志》(JAMA，由美国医学会出版的同行评审医学期刊)中指出，根据联邦法 律，处方药广告必须"公平平衡"地呈现药物的风险与益处。 他还特别提到FDA的执法力度已大幅减弱：在20世纪90年代末，FDA每年会发出数百封警告信，而2023 年全年仅发出1封，2024年至今则一封未发。 对此，Hims & Hers的一位发言人回应称，公司的"超级碗广告并未宣传任何一种特定疗法或解决方 案"。 该发言人在电子邮件声明中表示："相反，广告旨在通过展示肥胖问题的影响，以及民众难以获得能挽 救生命的全面减重医疗服务这一现 ...